340B Updates

Clinical Insights: August 30, 2018

Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval AltrenoTM (tretinoin) – August 24, 2018 – Ortho Dermatologics, one of the largest prescription dermatology healthcare businesses in the world, announced that the U.S. Food and Drug…

Read More...

Clinical Insights: January 15, 2018

Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Formulation Approval No new updates.   New Indication Approval Lynparza® (olaparib) – January 12, 2018 – The Food and Drug Administration…

Read More...

Clinical Insights: December 12, 2017

Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Lonhala™ Magnair™ (glycopyrrolate) – December 5, 2017 – Sunovion Pharmaceuticals Inc. (Sunovion) announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application…

Read More...

Clinical Insights: November 13, 2017

Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Heplisav-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] – New Vaccine Approval – November 9, 2017 – Dynavax Technologies Corporation announced that the U.S. Food and Drug Administration…

Read More...

Clinical Insights: October 2, 2017

Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Verzenio™ (abemaciclib) – September 28, 2017 – The U.S. Food and Drug Administration approved Verzenio™ (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth…

Read More...